Replies to post #424099 on Amarin Corp Plc (AMRN)

[ORBAPU]

Here is a study of branded EPADEL vs. generic from 2020.

https://www.scirp.org/journal/paperinformation?paperid=103416

Methods and Results: We investigated the differences in the serum levels of EPA, docosahexaenoic acid (DHA) and arachidonic acid (AA), and the EPA/AA ratios through blood sampling six months after daily administration of 1800 mg of EPADEL and a generic EPA drug was initiated for 96 patients with cardiovascular diseases. All patients received these PUFA treatments while continuing with baseline therapy. After 6 months of administration, EPADEL produced better results than the generic (G) product.